Abstract

BUENO ARIAS, Guadalupe Margarita et al. Tapentadol, a new horizon in the treatment of diabetic peripheral painful neuropathy. Review of literature. Acta méd. Grupo Ángeles [online]. 2018, vol.16, n.1, pp.41-46. ISSN 1870-7203.

The prevalence diabetes mellitus is increasing and complications are becoming more frequent, one of the most common complications, is peripheral diabetic neuropathy, which occurs in 30 to 50% of patients; of these, 10 to 20% have pain. The mechanism by which the pain is presented is not well established, but has been associated with chronic conditions of hyperglycemia, and cardiovascular risk factors. The pain associated with this condition is chronic and difficult to manage, increasing morbidity and mortality, as well as health costs. There are studies that demonstrate that opiates are the most prescribed medications for the management of chronic pain of this disease, but because of their adverse effects, patients do not have good attachment to the treatment, causing the suspension of this. Tapentadol, recently approved by the FDA for the management of pain of peripheral diabetic neuropathy; causes by its double action an effective management of the pain, with diminished of the adverse effects that are presented commonly with opioids. It is well tolerated by the elderly and patients with moderate kidney disease or mild liver disease.

Keywords : Tapentadol; diabetic neuropathy; neuralgia; analgesics opioid; neurotransmitter uptake inhibitors.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )